Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AZASITE is an ophthalmic solution containing azithromycin monohydrate, a macrolide antibiotic approved in 2007 for treating bacterial eye infections. Administered as topical drops, it provides sustained antimicrobial activity in ocular tissues. The drug targets patients with bacterial conjunctivitis and related ophthalmic infections.
Product approaching loss of exclusivity with minimal Part D penetration; brand team is likely focused on defending market share against generic and OTC alternatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Determine the Effect of Azasite on Corneal Surface Irregularity
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
Worked on AZASITE at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAZASITE currently shows zero linked job openings, reflecting its LOE-approaching status and minimal commercial expansion. Working on this product offers experience in mature brand defense and generic transition management, but limited career advancement or scaling opportunities within the brand itself.